Regulatory Risk Assessment of Pharmaceuticals in the Environment: Current Practice and Future Priorities

被引:6
|
作者
Oldenkamp, Rik [1 ,2 ]
Hamers, Timo [1 ]
Wilkinson, John [3 ]
Slootweg, Jaap [4 ]
Posthuma, Leo [4 ,5 ]
机构
[1] Vrije Univ Amsterdam, Amsterdam Inst Life & Environm, Fac Sci, Amsterdam, Netherlands
[2] Univ Amsterdam, Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands
[3] Univ York, Environm & Geog Dept, York, England
[4] RIVM, Ctr Sustainabil Environm & Hlth, Bilthoven, Netherlands
[5] Radboud Univ Nijmegen, Dept Environm Sci, Nijmegen, Netherlands
关键词
Chemical regulation; ecological risk assessment; pharmaceuticals; species sensitivity distributions; PERSONAL CARE PRODUCTS; TRIGGER VALUES; IN-VITRO; MIXTURES;
D O I
10.1002/etc.5535
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
How can data on the occurrence of pharmaceuticals and personal care products (PPCPs) in the environment and the quality of ecosystems exposed to PPCPs be used to determine whether current regulatory risk assessment schemes are effective? This is one of 20 "big questions" concerning PPCPs in the environment posed in a landmark review paper in 2012. Ten years later, we review the developments around this question, focusing on the first P in PPCPs, that is, pharmaceuticals, or more specifically the active ingredients included in them (active pharmaceutical ingredients, APIs). We illustrate how extensive data on both the occurrence of APIs and the ecotoxicological sensitivity of aquatic species to them can be used in a retrospective risk assessment. In the Netherlands, current regulatory risk assessment schemes offer insufficient protection against direct ecotoxicological effects from APIs: the toxic pressure exerted by the 39 APIs included in our study exceeds the policy-related protective threshold of 0.05 (the "95%-protection level") in at least 13% of sampled surface waters. In general, anti-inflammatory and antirheumatic products (e.g., diclofenac, ibuprofen) contributed most to the overall toxic pressure, followed by sex hormones and modulators of the genital system (e.g., ethinylestradiol) and psychoanaleptics (e.g., caffeine). We formulated three open questions for future research. The first relates to improving the availability and accessibility of good-quality ecotoxicity data on pharmaceuticals for the global scientific, regulatory, and general public. The second relates to the adaptation of regulatory risk assessment frameworks for developing regions of the world. The third relates to the integration of effect-based and ecological approaches into regulatory risk assessment practice. Environ Toxicol Chem 2023;00:1-12. (c) 2022 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC.
引用
收藏
页码:611 / 622
页数:12
相关论文
共 50 条
  • [21] Pharmaceuticals in the environment - A human risk?
    Christensen, FM
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1998, 28 (03) : 212 - 221
  • [22] The environmental risk assessment of human pharmaceuticals in the overall EU regulatory affairs process
    Laenge, Reinhard
    Steger-Hartmann, Thomas
    Schweinfurth, Hermann
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 45 (03) : 223 - 228
  • [23] Current Regulatory Risk Assessment Procedure and Regulatory Concerns with Using Quantitative Genetic Tox Data for Risk Assessment
    Froetschl, Roland
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2022, 63 : 59 - 60
  • [24] Current situation and future prognosis of health, safety and environment risk assessment of nanomaterials in South Africa
    Gulumian, Mary
    Thwala, Melusi
    Makhoba, Xolani
    Wepener, Victor
    SOUTH AFRICAN JOURNAL OF SCIENCE, 2023, 119 (1-2) : 3 - 7
  • [25] Risk assessment in anaphylaxis:: Current and future approaches
    Simons, F. Estelle R.
    Frew, Anthony J.
    Ansotegui, Ignacio J.
    Bochner, Bruce S.
    Golden, David B. K.
    Finkelman, Fred D.
    Leung, Donald Y. M.
    Lotvall, Jan
    Marone, Gianni
    Metcalfe, Dean D.
    Mueller, Ulrich
    Rosenwasser, Lanny J.
    Sampson, Hugh A.
    Schwartz, Lawrence B.
    van Hage, Marianne
    Walls, Andrew F.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (01) : S2 - S24
  • [26] Current and future approaches to neurotoxicity risk assessment
    Slikker, W
    Sobotka, TJ
    NEUROPROTECTIVE AGENTS - THIRD INTERNATIONAL CONFERENCE, 1997, 825 : 406 - 418
  • [27] Domestic and family violence perpetrator screening and risk assessment in Queensland: Current practice and future opportunities
    Meyer, Silke
    Helps, Nicola
    Fitz-Gibbon, Kate
    TRENDS AND ISSUES IN CRIME AND CRIMINAL JUSTICE, 2023, (660):
  • [28] Assessment of Pharmaceuticals Fate in a Model Environment
    Xavier Domènech
    Marc Ribera
    José Peral
    Water, Air, & Soil Pollution, 2011, 218 : 413 - 422
  • [29] Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment
    Cunningham, Virginia L.
    Binks, Stephen P.
    Olson, Michael J.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2009, 53 (01) : 39 - 45
  • [30] PHARMACEUTICALS IN AQUATIC ENVIRONMENT. FATE AND BEHAVIOR, ECOTOXICOLOGY AND RISK ASSESSMENT - A REVIEW
    Gworek, Barbara
    Kijenska, Marta
    Zaborowska, Magdalena
    Wrzosek, Justyna
    Tokarz, Lidia
    Chmielewski, Jaroslaw
    ACTA POLONIAE PHARMACEUTICA, 2019, 76 (03): : 397 - 407